Companies › BlossomHill Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BH-30236 | – | Phase 1 | Leukemia | Jun 2027 |
| BH-30643 Dual EGFR/HER2 inhibitor | EGFR, HER2 | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06501196 | BH-30236 | Phase 1 | Leukemia | Oncology | Jun 2027 |
| NCT06706076 | BH-30643 | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Oncology | Jan 2029 |
Cash of $95m on 2026-06-30; operating cash outflow about $90m a year; runway about 13 months at that burn, to Jul 2027
Press releases filed as 8-K in the last year:
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Beijing Biotech Pierre Fabre Medicament Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.